Progesterone Receptor A Promotes Invasiveness and Metastasis of Luminal Breast Cancer by Suppressing Regulation of Critical MicroRNAs by Estrogen

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2017 Nov 23

PMID 29162724

Citations 20

Authors

Thomas McFall

Brooke McKnight

Rayna Rosati

Seongho Kim

Yanfang Huang

Nerissa Viola-Villegas

Manohar Ratnam

Affiliations

Soon will be listed here.

Abstract

Distal metastasis of luminal breast cancer is frequent and incurable, yet the metastasis mechanisms are poorly understood. Estrogen, even at postmenopausal concentrations, suppresses invasiveness of luminal breast cancer cells through the estrogen receptor (ER). Invasive tumors overexpress the short progesterone receptor A (PR-A) isoform. Even at postmenopausal concentrations, progesterone activates PR-A, inducing invasiveness by counteracting estrogen's effects, particularly when cells are hypersensitized to progesterone by PR-A overexpression. To interrogate the role of this cross-talk in metastasis, we investigated selective cross-talk mechanisms of PR-A with ER. We developed a quantitative PCR-based lymph node infiltration assay to address the slowness of metastasis of tumor xenografts. We found that 15 microRNAs (miRNAs) are regulated by progesterone via PR-A, but not the longer PR-B isoform, with increased progesterone sensitivity when PR-A was overexpressed. Two of these miRNAs whose induction (miR-92a-3p) or repression (miR-26b-5p) by estrogen was suppressed by progesterone plus PR-A were critical for the PR-A-ER cross-talk causing a gene-regulatory pattern of invasiveness and metastasis and complete rescue of invasiveness Constitutive expression of miR-92a-3p or inhibition of miR-26b-5p profoundly suppressed metastasis. Finally, in primary breast tumors, PR-A expression was correlated negatively with miR-92a-3p expression and positively with miR-26b-5p expression. Therefore, hormonal cross-talk of PR-A with ER is probably a fundamental mechanism that enables metastasis of luminal breast cancer. Moreover, miRNA biomarkers of hyperactive PR-A may help predict metastatic potential of luminal breast tumors. Further, miR-92a-3p and miR-26b-5p may reveal target pathways for selective intervention to suppress hormone-regulated metastasis, both pre- and postmenopause.

Citing Articles

HIF-1α knockdown suppresses breast cancer metastasis via epithelial mesenchymal transition Abrogation.

Zhao J, Zhang H, Liu Y, Lu G, Wang Z, Mo Q Heliyon. 2024; 10(19):e37900.

PMID: 39386828 PMC: 11462230. DOI: 10.1016/j.heliyon.2024.e37900.

Narratives of resilience: Understanding Iranian breast cancer survivors through health belief model and stress-coping theory for enhanced interventions.

Mehrabizadeh M, Zaremohzzabieh Z, Zarean M, Ahrari S, Ahmadi A BMC Womens Health. 2024; 24(1):552.

PMID: 39375669 PMC: 11459698. DOI: 10.1186/s12905-024-03383-7.

Sex-Biased Expression and Response of microRNAs in Neurological Diseases and Neurotrauma.

Geleta U, Prajapati P, Bachstetter A, Nelson P, Wang W Int J Mol Sci. 2024; 25(5).

PMID: 38473893 PMC: 10931569. DOI: 10.3390/ijms25052648.

Progesterone Receptor Expression Level Predicts Prognosis of Estrogen Receptor-Positive/HER2-Negative Young Breast Cancer: A Single-Center Prospective Cohort Study.

Kwak Y, Jang S, Choi J, Lee H, Shin D, Park Y Cancers (Basel). 2023; 15(13).

PMID: 37444546 PMC: 10341192. DOI: 10.3390/cancers15133435.

Targeting Nuclear Receptors in Lung Cancer-Novel Therapeutic Prospects.

Gangwar S, Kumar A, Yap K, Jose S, Parama D, Sethi G Pharmaceuticals (Basel). 2022; 15(5).

PMID: 35631448 PMC: 9145966. DOI: 10.3390/ph15050624.

References

Miyamoto K, Seki N, Matsushita R, Yonemori M, Yoshino H, Nakagawa M . Tumour-suppressive miRNA-26a-5p and miR-26b-5p inhibit cell aggressiveness by regulating PLOD2 in bladder cancer. Br J Cancer. 2016; 115(3):354-63. PMC: 4973152. DOI: 10.1038/bjc.2016.179. View

Dai D, Wolf D, Litman E, White M, Leslie K . Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res. 2002; 62(3):881-6. View

Dunnwald L, Rossing M, Li C . Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007; 9(1):R6. PMC: 1851385. DOI: 10.1186/bcr1639. View

Kent O, Mendell J . A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 2006; 25(46):6188-96. DOI: 10.1038/sj.onc.1209913. View

Giangrande P, Kimbrel E, Edwards D, McDonnell D . The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol Cell Biol. 2000; 20(9):3102-15. PMC: 85605. DOI: 10.1128/MCB.20.9.3102-3115.2000. View

Lin V, Aw S, Tan M, Ng E, Chan V, Ho G . Progestins inhibit the growth of MDA-MB-231 cells transfected with progesterone receptor complementary DNA. Clin Cancer Res. 1999; 5(2):395-403. View

Gomez-Fernandez C, Daneshbod Y, Nassiri M, Milikowski C, Alvarez C, Nadji M . Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer. Am J Clin Pathol. 2008; 130(6):879-82. DOI: 10.1309/AJCPD1AO3YSYQYNW. View

Missmer S, Eliassen A, Barbieri R, Hankinson S . Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst. 2004; 96(24):1856-65. DOI: 10.1093/jnci/djh336. View

Liang Y, Benakanakere I, Besch-Williford C, Hyder R, Ellersieck M, Hyder S . Synthetic progestins induce growth and metastasis of BT-474 human breast cancer xenografts in nude mice. Menopause. 2010; 17(5):1040-7. PMC: 2923240. DOI: 10.1097/gme.0b013e3181d3dd0c. View

10.

Newton C, Samuel D, James V . Aromatase activity and concentrations of cortisol, progesterone and testosterone in breast and abdominal adipose tissue. J Steroid Biochem. 1986; 24(5):1033-9. DOI: 10.1016/0022-4731(86)90356-0. View

11.

Shatnawi A, Tran T, Ratnam M . R5020 and RU486 act as progesterone receptor agonists to enhance Sp1/Sp4-dependent gene transcription by an indirect mechanism. Mol Endocrinol. 2006; 21(3):635-50. DOI: 10.1210/me.2006-0274. View

12.

Zhu A, Kang N, He L, Li X, Xu X, Zhang H . MiR-221 and miR-26b Regulate Chemotactic Migration of MSCs Toward HGF Through Activation of Akt and FAK. J Cell Biochem. 2015; 117(6):1370-83. DOI: 10.1002/jcb.25428. View

13.

Richer J, Jacobsen B, Manning N, Abel M, Wolf D, Horwitz K . Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem. 2001; 277(7):5209-18. DOI: 10.1074/jbc.M110090200. View

14.

Bakker G, Portengen H, de Jong F, Foekens J, Klijn J . Treatment of breast cancer with different antiprogestins: preclinical and clinical studies. J Steroid Biochem Mol Biol. 1990; 37(6):789-94. DOI: 10.1016/0960-0760(90)90421-g. View

15.

Wickramasinghe N, Manavalan T, Dougherty S, Riggs K, Li Y, Klinge C . Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res. 2009; 37(8):2584-95. PMC: 2677875. DOI: 10.1093/nar/gkp117. View

16.

Ibrahim Y, Byron S, Cui X, Lee A, Yee D . Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2. Mol Cancer Res. 2008; 6(9):1491-8. PMC: 4000707. DOI: 10.1158/1541-7786.MCR-07-2173. View

17.

McDonnell D, Goldman M . RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism. J Biol Chem. 1994; 269(16):11945-9. View

18.

Gilam A, Shai A, Ashkenazi I, Sarid L, Drobot A, Bickel A . MicroRNA regulation of progesterone receptor in breast cancer. Oncotarget. 2017; 8(16):25963-25976. PMC: 5432230. DOI: 10.18632/oncotarget.15657. View

19.

Lin V, Eng A, Hen N, Ng E, Chowdhury S . Effect of progesterone on the invasive properties and tumor growth of progesterone receptor-transfected breast cancer cells MDA-MB-231. Clin Cancer Res. 2001; 7(9):2880-6. View

20.

Li Q, Kannan A, DeMayo F, Lydon J, Cooke P, Yamagishi H . The antiproliferative action of progesterone in uterine epithelium is mediated by Hand2. Science. 2011; 331(6019):912-6. PMC: 3320855. DOI: 10.1126/science.1197454. View